81. Innovations for narcolepsy, Greg Divis, CEO, Avadel Pharmaceuticals

Gregory J. Divis serves as Avadel’s Chief Executive Officer and a member of Avadel’s Board of Directors. Greg was appointed CEO in June of 2019, after previously serving in several leadership roles within the company, including Chief Operating Officer, Executive Vice President, and Chief Commercial Officer. Greg brings over 30 years of experience in building and leading business and financial operations within the pharmaceutical industry. Prior to joining Avadel, Greg served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. He also served as President and Chief Executive Officer of Lumara Health, a specialty branded pharmaceutical company focused on women's health. Prior to Lumara, Greg held general management, sales, marketing, and business development roles at Schering-Plough, which was acquired by Merck & Co., Inc., and Sanofi-Aventis. Greg earned his bachelor's degree from the University of Iowa.